Used in the treatment of acute ischemic stroke, this antibody targets glycoprotein VI (GPVI) on platelets to inhibit platelet aggregation without significantly affecting hemostasis. By selectively blocking collagen-mediated platelet activation, it reduces the risk of thrombus formation in cerebral arteries. Its mechanism offers potential for safer antithrombotic therapy with lower bleeding risk compared to conventional antiplatelet drugs. Currently investigated in clinical trials for efficacy in preventing early recurrence of stroke and improving neurological outcomes.